Company taps John R. Quain, Norbert Gleicher, MD, Carol Hanna, Ph.D, Jon Hennebold, Ph.D, and Stephen Turner, Ph.D to its world-class team to advance responsible genomic medicine.

Inherited diseases should not dictate human fate. Today, with advances in genomics, a different future is within reach. In this new era of genomic medicine, Manhattan Genomics, led by serial biotech entrepreneur Cathy Tie and renowned researcher Eriona Hysolli, Ph.D., announced its full scientific contributions team. This world-class group unites pioneers across bioethics, reproductive medicine, and computational genomics to guide the company's mission to advance breakthrough research in preventative genomic therapies.

“This is our generation’s Manhattan Project,” said co-founder Cathy Tie. “To ensure no child inherits a preventable genetic disease. Families are desperate for solutions, and we are committed to eliminate inherited diseases that devastate families across generations. With the brightest minds in bioethics and reproductive medicine guiding our work, we’re building the foundation for responsible genomic medicine, advancing cures under the strongest ethical and regulatory guardrails while positioning the U.S. to lead globally in this transformative field.”

Leading scientist in the field of gene therapy in gametes and preimplantation embryos and the inventor of mitochondrial replacement therapy (MRT), the world's first form of germline gene therapy for mtDNA disease, Shoukhrat Mitalipov, Ph.D said, “I strongly support Manhattan Genomic's mission to correct and prevent transmission of genetic diseases. This critical work demands thoughtful conversation with all stakeholders, and Manhattan Genomics is highly focused on bridging those conversations."

Manhattan Genomics is advancing next-generation medical technologies to correct harmful mutations at the embryonic stage. The company’s singular mission is to prevent severe inherited conditions, such as Huntington’s Disease, Cystic Fibrosis, and Sickle Cell Anemia, in future generations.

"To undertake a mission as ambitious as the Manhattan Project, we must have the people who pioneered the key technologies that will usher in the next stage of human health," said co-founder Eriona Hysolli, Ph.D. "We are thrilled to build out this exceptional team who will help change the future of human health."

To ensure its work is grounded in transparency and ethical responsibility, Manhattan Genomics has tapped John R. Quain, an Ethics Fellow in the Bioethics Program at the Icahn School of Medicine at Mount Sinai in New York City. His work in ethics has focused in particular on bioethical issues related to the application of genetic research, from food and agriculture to the treatment of human diseases.

“This technology presents extraordinary opportunities, so it’s critical that it moves forward and does so ethically,” said John R. Quain. “Our goal is to reduce suffering for the families facing these inherited mutations in a way that is scientifically rigorous and ethically sound. To do that, there has to be strong oversight, a commitment to patient safety, and we have to ensure that we communicate clearly about our work so that people understand the tremendous potential public health benefits."

To round out its distinguished team, four leading scientific contributors and subject-matter experts have joined Manhattan Genomics, including:

• Norbert Gleicher, MD – Medical Director and Chief Scientist of New York’s Center for Human Reproduction (CHR). A world-renowned clinical scientist and authority on ovarian aging and diminished ovarian reserve. A visiting scientist at Rockefeller University and a visiting professor at the Medical University of Austria, in Vienna.

• Carol Hanna, Ph.D & Jon Hennebold, Ph.D – Directors and professors at Oregon National Primate Research Center with expertise in non-human primate assisted reproductive technologies and embryo biology at the world’s premier primate research institution.

• Stephen Turner, Ph.D – Former Head of Genomics Strategy at Colossal Biosciences and current Professor of data science at the University of Virginia. Specialist in computational modeling and infrastructure for polygenic traits and disease prediction.

Manhattan Genomics is focused on a future where groundbreaking genomic medicines are the standard of care. Its strategy is centered on generating high-quality, actionable data through transparent science, guided by progressive ethics frameworks that put patients' medical needs first. By adhering to these principles, the company will establish the United States as the world's undisputed leader in genomic medicines.

About Manhattan Genomics

Manhattan Genomics is a biotechnology company with the mission of eliminating inherited genetic diseases through ethical gene correction at the embryonic stage. Founded by biotech entrepreneur Cathy Tie and scientist Eriona Hysolli, Ph.D., the company is pioneering advanced technologies under strict U.S. regulatory oversight, guided by world-class researchers, ethicists and clinicians. For more information, visit manhattangenomics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251030506331/en/